In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end- to-end biologics CDMO Mabion hav...
Bristol Myers Squibb’s announcement that the US Food and Drug Administration has approved the removal of REMS programs an...
Clinical-stage biotech company Noxopharm Limited (ASX:NOX) is pleased to announce that recruitment activities are progressing rapidly and on sche...
Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Ph...
EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial. ...
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, announces that the FDA has granted the Regenerative...
Nutriband Inc. a company engaged in the development of prescription transdermal pharmaceutical products, announced that it has completed commercial...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...
Agreement builds on PharmaJet’s strategy to be the best-in-class delivery system for novel DNA- and RNA-based vaccines and immunotherapies usin...
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded...
Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel imm...
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-rel...
© 2025 Biopharma Boardroom. All Rights Reserved.
